信达生物(01801.HK)雅高(03313.HK)获纳入MSCI中国指数组合 股价涨近4.5%及17%
雅高控股(03313.HK)获纳入MSCI中国指数组合，该股承过去五连涨势，今早最多再升22%，高见7.94元，创逾一个月高，现造7.58元，续涨16.6%，一向薄弱成交增至440万股。同获纳入该指数的平安好医生(01833.HK)、翰森制药(03692.HK)及信达生物制药(01801.HK)也继续造好，最高见56.5元/25.7元/25.15元，现造56元/25.4元/25元，依次续升近2%-4.5%。同为该组合新贵之一的雅生活服务(03319.HK)高见25.7元，暂受制本周三盘中所创纪录高位26元，现造25.5元，回升1.4%。
不过，同获纳入该指数的正荣地产(06158.HK)由八个月高位连吐第二天，今早高开见5.45元遇压，掉头低见5.24元，现造5.28元，续吐2%，股价失守10天及20天线(5.38元)；同为该组合新贵之一的深高速(00548.HK)今早高开报10.96元欠承接，未能进一步突破前两天盘中所造纪录高位11.06元，掉头低见10.68元，守稳10天线(10.61元)，现造10.78元，倒跌1.3%。
反观，遭剔除MSCI中国指数在本港上市7只股份，除五矿资源(01208.HK)窄幅靠稳报1.91元外，余下同仁堂科技(01666.HK)、恒腾网络(00136.HK)、鞍钢(00347.HK)、中国东方(00581.HK)、美图公司(01357.HK)及四环医药(00460.HK)全部跌2%-3.5%，分别报7.42元/0.122元/2.71元/2.81元/1.71元/1.11元。
MSCI明晟公布全球标准指数成份股半年度检讨结果显示，中国指数新增218只股份，包括本港上市雅高控股、雅生活服务、翰森制药、信达生物制药、平安好医生、中联重科(01157.HK)、深高速、正荣地产、九仓(00004.HK)、中国东方教育(00667.HK)及中国联塑(02128.HK)等。上述所有变动将於11月26日收市後生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
